"label","instanceType","uuid:ID","id","rationale","description","name"
"","StudyDesign","a8cd993a-28a3-4390-9f86-87e31a7d7eb4","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1"
